- Home
- NVMI vs MDGL Comparison
NVMI vs MDGL Comparison
Compare NVMI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVMI
- MDGL
- Stock Information
- Founded
- NVMI 1993
- MDGL 2011
- Country
- NVMI Israel
- MDGL United States
- Employees
- NVMI N/A
- MDGL N/A
- Industry
- NVMI Electronic Components
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- NVMI Technology
- MDGL Health Care
- Exchange
- NVMI Nasdaq
- MDGL Nasdaq
- Market Cap
- NVMI 6.3B
- MDGL 6.4B
- IPO Year
- NVMI 2000
- MDGL N/A
- Fundamental
- Price
- NVMI $244.91
- MDGL $293.64
- Analyst Decision
- NVMI Strong Buy
- MDGL Buy
- Analyst Count
- NVMI 7
- MDGL 14
- Target Price
- NVMI $238.33
- MDGL $351.67
- AVG Volume (30 Days)
- NVMI 167.3K
- MDGL 413.3K
- Earning Date
- NVMI 02-13-2025
- MDGL 02-26-2025
- Dividend Yield
- NVMI N/A
- MDGL N/A
- EPS Growth
- NVMI 26.92
- MDGL N/A
- EPS
- NVMI 5.34
- MDGL N/A
- Revenue
- NVMI $611,849,000.00
- MDGL $76,813,000.00
- Revenue This Year
- NVMI $30.83
- MDGL N/A
- Revenue Next Year
- NVMI $18.41
- MDGL $194.49
- P/E Ratio
- NVMI $45.84
- MDGL N/A
- Revenue Growth
- NVMI 14.38
- MDGL N/A
- 52 Week Low
- NVMI $138.24
- MDGL $168.25
- 52 Week High
- NVMI $249.01
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- NVMI 81.47
- MDGL 45.07
- Support Level
- NVMI $209.68
- MDGL $266.44
- Resistance Level
- NVMI $249.01
- MDGL $343.97
- Average True Range (ATR)
- NVMI 7.34
- MDGL 17.83
- MACD
- NVMI 3.66
- MDGL -4.57
- Stochastic Oscillator
- NVMI 92.41
- MDGL 35.08
About NVMI Nova Ltd.
Nova Ltd is a semiconductor equipment manufacturer. The company provides metrology solutions for process control used in semiconductor manufacturing. The company offers in-line optical and x-ray stand-alone metrology systems, as well as integrated optical metrology systems. The product range consists of Nova 2040, Nova 3090Next, Nova i500 and i500 Plus, Nova T500, Nova T600, Nova V2600, HelioSense 100, Nova Hybrid Metrology solution, NovaMars. The company generates the majority of its revenue from China. Geographically the company has its business spread across the region of Taiwan, Korea, China, the United States, and Europe.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.